Danish pharmaceutical giant Novo Nordisk gains significant access with the approval of its weight-loss drug Wegovy in China. This move grants Novo Nordisk entry into the world's second-largest economy, targeting a growing population facing obesity challenges. Key Considerations: Wegovy targets patients with a Body Mass Index (BMI) of 30 or higher alongside...
Novo Nordisk ( NYSE:NVO ) stands as a beacon of innovation, continually pushing boundaries in the treatment of diabetes and obesity. However, despite its recent successes, the company finds itself navigating the delicate balance between bullish growth projections and meeting market expectations. The latest buzz surrounds Novo Nordisk's weight-loss blockbuster,...
Novo Nordisk (NVO) hit the 1D MA50 (blue trend-line) again for the first time since December 18 2023 and after a long time it gives buy signals again. The correction came after the March 07 rejected at the top of the (dotted) Channel Up, following overbought 1D RSI levels before that for 2 weeks. That is a pattern consistent with all previous Higher High...
In the ever-evolving landscape of technological innovation, a new wave of AI computers is poised to revolutionize computation as we know it. With processors designed specifically for AI programs, these machines unlock a realm of possibilities for individuals, governments, and scientific organizations alike. At the forefront of this transformative wave is Danish...
Novo Nordisk ( NYSE:NVO ) made waves in the pharmaceutical industry as its stock skyrocketed to unprecedented heights following the announcement of groundbreaking results from its experimental oral weight-loss drug, amycretin. The drugmaker's innovative approach, which combines GLP-1 and amylin hormones, surpassed expectations by demonstrating remarkable efficacy...
Novo Nordisk is emerging from a textbook volatility compression pattern (VCP) - the setup made famous by Mark Minervini. Notice the series of progressively shallower pullbacks from left to right as supply has been absorbed by buyers. NVO is a market-leading stock by all accounts. Shares are up 75% over the last twelve months with no signs of slowing down. This is...
Baxter has been obliterated on the back of Ozempic. This stocks is hitting multidecade support, in a very oversold condition on the larger time frames. You also have a Monthly RSI divergence occurring which could help the technical bounce scenario .
Analyzing the options chain and the chart patterns of NVO Novo Nordisk prior to the earnings report this week, I would consider purchasing the $162.5 strike price Calls with an expiration date of 2023-8-18, for a premium of approximately $6.85. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Looking...
Missed the stock. Saw a lot of hype about the drug the last couple of years. Would have loved to have long dated options on it. Will be interesting to see what it does.
Another impulse done and dusted. Divergent, now looking out of steam. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore...
Today NVO got over resistance and did not look back. I noticed some bullish sweep call flow today that caught my attention. The 2022 dated calls had a low OI. It gapped up today at open with strong conviction. I am planning on entering a trade at a dip near today's gap placing the 2.618 as a target. I'll be looking at the 78-80 area as a possible stop loss in case...
No retracement yet of the first up-leg, this is just starting!
Price action near $57.5 will determine where it will go next. - it has shown strength when breaking through $57.5 on larger timeframes - NVO is a buy - A pullback to $57.5 would be a good long entry point, provided that there are no heavy sell off during this pullback. - new ATH likely, given some time.
In this chart we're looking at NVO on the 1W chart as price has consolidated into an ascending triangle . Price has broken through the horizontal boundary around $58. After price prints a 1W candle (1 day left) through $59.77 breakout will be confirmed. This ascending triangle has a price target of around $85 for about a ~46% gain. Price has good momentum as...